837 related articles for article (PubMed ID: 30076486)
1. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
Kuruvilla J; Sasmita AO; Ling APK
Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
[TBL] [Abstract][Full Text] [Related]
2. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
[TBL] [Abstract][Full Text] [Related]
3. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
Zhang X; Wang L; Liu M; Li D
Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
[TBL] [Abstract][Full Text] [Related]
6. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
[TBL] [Abstract][Full Text] [Related]
7. [The CRISPR-Cas system: beyond genome editing].
Croteau FR; Rousseau GM; Moineau S
Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage.
Sun J; Carlson-Stevermer J; Das U; Shen M; Delenclos M; Snead AM; Koo SY; Wang L; Qiao D; Loi J; Petersen AJ; Stockton M; Bhattacharyya A; Jones MV; Zhao X; McLean PJ; Sproul AA; Saha K; Roy S
Nat Commun; 2019 Jan; 10(1):53. PubMed ID: 30604771
[TBL] [Abstract][Full Text] [Related]
10. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
[TBL] [Abstract][Full Text] [Related]
12. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
15. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.
Fatehi S; Marks RM; Rok MJ; Perillat L; Ivakine EA; Cohn RD
Hum Gene Ther; 2023 May; 34(9-10):388-403. PubMed ID: 37119122
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of viral vectors as vehicles for DMD gene editing.
Maggio I; Chen X; Gonçalves MA
Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
Salsman J; Masson JY; Orthwein A; Dellaire G
Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated correction of human genetic disease.
Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
